Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03452202 · ClinicalTrials.gov registry record · NA
Using tDCS in Speech-based Stroke Rehabilitation
A NA study of Apraxia of Speech, sponsored by NYU Langone Health.
- Recruiting
- Registry status
- NA
- Development phase
- 24
- Enrollment target
- 2
- Study locations
NCT03452202: Recruiting NA study of Apraxia of Speech, sponsored by NYU Langone Health.
NCT03452202 is a NA study of Apraxia of Speech that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 24 participants, below the 37-participant average among 5 other Apraxia of Speech trials with a reported enrollment target (35% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03452202, a NA study of Apraxia of Speech, is actively recruiting participants, sponsored by NYU Langone Health.
- RECRUITING
- Registry status
- NA
- Development phase
- 24 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to determine whether the effect of treatment for acquired speech impairment can be enhanced by combining effective behavioral treatment with non-invasive brain stimulation. Transcranial direct current stimulation (tDCS), which delivers low-intensity current to the scalp, and is a safe and well-tolerated approach that poses a non-significant risk to participants. tDCS provides low intensity neural stimulation which has been shown to facilitate motor learning in other domains of stroke rehabilitation such as arm motor learning but the potential to enhance speech motor learning has not been explored. This will be examined with a series of single-case experimental designs.
Primary Outcome
Subjects will be given speech production tasks. Recordings of tasks will be scored for accuracy to measure speech motor learning
Conditions Studied
Interventions
- DEVICE Soterix 1x1 line tDCS low-intensity stimulator
- DEVICE Sham
Study Locations (2)
New York
- New York University School of Medicine - New York
- Burke Rehabilitation Hospital - White Plains
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2019-01-11 |
| Est. Completion | 2026-10-30 |
| Phase | NA |
What NCT03452202 shows while recruiting
NCT03452202 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 37-participant average among 5 other Apraxia of Speech trials with a reported enrollment target (35% lower).
The record links to 1 condition, with Apraxia of Speech appearing as the primary indexed condition, and to 2 interventions - of which Soterix 1x1 line tDCS low-intensity stimulator is the first listed.
NCT03452202 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03452202 about?
NCT03452202 is a clinical study titled "Using tDCS in Speech-based Stroke Rehabilitation". The purpose of this study is to determine whether the effect of treatment for acquired speech impairment can be enhanced by combining effective behavioral treatment with non-invasive brain stimulation. Transcranial direct current stimulation (tDCS), which delivers low-intensity current to the scalp,...
What is the current status of trial NCT03452202?
This trial is currently recruiting. It is a NA study. The enrollment target is 24 participants. The study started on 2019-01-11. Estimated completion is 2026-10-30.
What conditions does trial NCT03452202 study?
This clinical trial studies the following conditions: Apraxia of Speech.
What interventions are being tested in trial NCT03452202?
The interventions under investigation include: Soterix 1x1 line tDCS low-intensity stimulator (DEVICE), Sham (DEVICE).
Who is sponsoring clinical trial NCT03452202?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03452202 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Apraxia of Speech
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Motor Imagery for Treatment Enhancement and Efficacy in Persons With Apraxia of Speech
RECRUITING · NA
-
Measuring Aided Language Development
RECRUITING · NA
-
Treating Primary Progressive Aphasia and Apraxia of Speech Using Non-invasive Brain Stimulation
ACTIVE NOT RECRUITING · NA
-
Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech
RECRUITING · Phase 4
-
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI